Flag­ship's lat­est boast? A start­up that will 'rev­o­lu­tion­ize treat­men­t' for 'nine­ty per­cent of hu­man ill­ness'

Christo­pher Austin has spent the last decade build­ing a gov­ern­ment agency known in part for help­ing change drug de­vel­op­ment for rare dis­eases. Now, he’d like to fo­cus on the far more com­mon ones.

On Wednes­day Austin and the VC firm Flag­ship Pi­o­neer­ing an­nounced the launch of — and a $75 mil­lion Se­ries A for — Vesal­ius Ther­a­peu­tics, a biotech that is try­ing to “rev­o­lu­tion­ize the treat­ment of the dis­eases that dri­ve nine­ty per­cent of hu­man ill­ness,” ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER